摘要
慢性粒细胞白血病是一类造血干细胞的恶性克隆性疾病,ph染色体是其特征性细胞遗传学标志,即t(9;22)(q34;ql1),存在BCR/ABL融合基因,现阶段造血干细胞移植是当前最有希望治愈CML的疗法,但受年龄、配型等限制,易发生移植物抗宿主病;复发率较高;传统的化疗、干扰素治疗也有副作用,因此,通过信号传导抑制剂抑制BCR-ABL酪氨酸激酶活性,从而阻止一系列信号传导来治疗CML是一个比较好的治疗方法,伊马替尼是一种酪氨酸激酶抑制剂是治疗慢性粒细胞白血病的靶向治疗药物,治疗疗效显著,但是并不能根治慢性粒细胞白血病,需要长期服药,一些患者出现耐药,导致治疗无效或复发。因此,寻求新的治疗方案至关重要。本文就慢性粒细胞白血病的耐药机制及治疗策略做一综述。
Chronic myeloid leukemia is a malignant clonal disease of hematopoietic stem cells, ph chromosome characteristic cytogenetic signs, t （9; 22） （q34; q11）, which presence of the BCR / ABL fusion gene, at this stage ofhematopoietic stem cellstransplanta- tion is the most promising cure for CML therapy, but is limited by age, matching, high incidence of graft-versus-host disease; higher rela- pse rate; conventional chemotherapy, interferon therapy side effects through signal transduction inhibitorinhibit the BCR-ABL tyrosine kinase activity, thereby preventing a series of signaling to the treatment of CML is a better treatment, imatinib, a tyrosine kinase inhibitor treatment of chronic myeloid leukemiadrugs, the treatment effect is significant, but it does not cure chronic myeloid leukemia, and require long-term medication, some patients resistant, resulting in ineffective treatment or recurrence. Therefore, the search for new treatment options is essential. The resistance mechanism of chronic myelogenous leukemia and treatment strategies.
出处
《现代生物医学进展》
CAS
2014年第5期975-977,共3页
Progress in Modern Biomedicine
基金
国家自然科学基金项目(208731111)
关键词
慢性粒细胞白血病
耐药机制
治疗策略
Chronic Myeloid Leukmia
Resistance mechanisms
Treatment Strategies
